CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) CFO Kelly Gold bought 10,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at approximately $39,600. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Kelly Gold also recently made the following trade(s):
- On Monday, August 3rd, Kelly Gold purchased 6,551 shares of CAMP4 Therapeutics stock. The shares were bought at an average cost of $1.65 per share, for a total transaction of $10,809.15.
CAMP4 Therapeutics Stock Up 18.2%
Shares of CAMP stock opened at $4.49 on Friday. The stock has a market capitalization of $281.75 million, a PE ratio of -1.94 and a beta of 0.27. CAMP4 Therapeutics Corporation has a 52-week low of $1.44 and a 52-week high of $7.75. The stock’s 50-day moving average price is $4.12 and its 200 day moving average price is $4.35.
Institutional Trading of CAMP4 Therapeutics
A number of institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new position in CAMP4 Therapeutics in the fourth quarter worth $70,000. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth $86,000. OMERS ADMINISTRATION Corp acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth $115,000. Goldman Sachs Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at about $115,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $36,000.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on CAMP shares. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Piper Sandler reiterated an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.56.
Read Our Latest Stock Report on CAMP
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
See Also
- Five stocks we like better than CAMP4 Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
